Autoimmune Encephalitis Clinical Trial
— POTAOfficial title:
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Epilepsy is a disorder of the brain in which people have repeated seizures. Autoimmune encephalitis (AE) is a rare cause of epilepsy. It is an inflammatory disease of the brain. This means that the body's own immune system attacks healthy brain tissue, just like it would if it were infected by a virus or a bacteria, by producing an army of proteins called 'antibodies' which go on to 'attack' healthy tissues. Seizures in AE typically do not respond well to classic 'anti-seizure medications'. Instead, medications which suppress the immune system are used. These can have significant side-effects and some patients will still continue to have seizures or experience a recurrence of AE-related epilepsy despite treatment. It is difficult to accurately predict who will experience these outcomes. This study aims to find ways of predicting and monitoring which people with AE are at greatest risk of these outcomes, so we can better direct them towards appropriate treatments. We will collect clinical information and samples of blood and cerebrospinal fluid (CSF, fluid surrounding the brain and spinal cord) from people with AE and 'control' participants with other neurological illnesses. Samples will be analysed for markers which may help predict or correlate with outcomes in AE and better understand this condition.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | November 2025 |
Est. primary completion date | November 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - AE participants over the age of 18 will be recruited if they meet the criteria for clinically probable or clinically definite Autoimmune Encephalitis as per Graus and colleagues 2016. - Neurological Control participants undergoing lumbar puncture as part of clinical care for other, non-encephalitis disorders (e.g. for investigation of headache where meningitis or encephalitis is not detected, for investigation and treatment of idiopathic intracranial hypertension) in Beaumont hospital will be recruited. Exclusion Criteria: AE participants - Under 18 years of age - Participants without AE or those with a definitive alternate diagnosis for presentation. Other neurological control participants will be excluded if they have a current or historic diagnosis of AE. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Royal College of Surgeons, Ireland | University of Oxford |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Other symptoms | Qualitiative analysis through semi-structured interview with participants and caregivers. | 1-3 years | |
Primary | Seizure frequency | >50% improvement in seizure frequency over time | 1-3 years | |
Primary | Functional status | Modified Rankin score | 1-3 years | |
Secondary | Cognitive ability | As measured by the Addenbrooke's Cognitive Examination. | 1-3 years | |
Secondary | Clinical status | As measured by the Clinical Assessment of severity in Autoimmune Encephalitis. | 1-3 years | |
Secondary | Mood/affect | Measured by the hospital anxiety and depression index | 1-3 years | |
Secondary | Quality of life | EQ-5D-5L (By EuroQOL, not an abbreviation) | 1-3 years | |
Secondary | Pain | Patient-Reported Outcomes Measurement Information System (PROMIS) Pain interference short form A | 1-3 years | |
Secondary | Fatigue | Fatigue Scale for Motor and Cognitive Funcitons | 1-3 years | |
Secondary | Fatigue | Modified Fatigue and Impact Scale | 1-3 years | |
Secondary | Sleep Quality | Pittsburgh Sleep Quality Index | 1-3 years | |
Secondary | Impulsivity | Barratt Impulsivity Index | 1-3 years | |
Secondary | Neuropsychiatric symptoms | Neuropsychiatric Inventory | 1-3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|